Why Amgen Stock Was Crushing It on Wednesday
One of the healthier stocks in the healthcare field Wednesday was (NASDAQ: AMGN). The biotech and pharmaceutical company published its third-quarter results the previous day after market close, and investors were obviously pleased. In mid-session trading Wednesday they were pushing the stock's price up by more than 8%.
The quarter saw Amgen lift its total revenue by 12% year over year to $9.6 billion, fueled by double-digit increases in the sales of key drugs. Net income not according to generally accepted accounting principles (GAAP) also rose, albeit more modestly. It ticked up by 1% to just under $3.06 billion, or $5.64 per share.
Image source: Getty Images.
Source Fool.com
Amgen Inc. Aktie
296,50 €
0,78 %
Die Community bevorzugt Amgen Inc., mit deutlich mehr Buy- (35) als Sell-Einschätzungen (3).
Das von der Community festgelegte Kursziel von 312 € für Amgen Inc. deutet auf ein leichtes Wachstumspotenzial im Vergleich zu 296.5 € hin.
